Semaglutide Initiation Halves Adult-Onset Seizure Risk in Type 2 Diabetes Patients

Adult-onset seizure represents a significant burden from acquired brain insults, yet effective disease-modifying preventive strategies remain limited. Patients with type 2 diabetes (T2D) are at increased risk for various neurological complications, including seizures, due to metabolic dysregulation and associated comorbidities. Current glucose-lowering drugs primarily target glycemic control, but their impact on neurological outcomes like seizure incidence is often not a primary focus. This study investigates whether semaglutide, a GLP-1 receptor agonist, offers a protective effect beyond glycemic management against adult-onset seizure in this vulnerable population.